GlassScriptPhysician profile
Roger A Hodge
NPI 1255370029
$2,613.56
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $1,156 · 2021: $398.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.10 | 2019-2021 | |
| Pfizer INC. | $218.03 | 2019-2020 | |
| Amgen INC. | $207.87 | 2019-2021 | |
| Allergan, INC. | $186.06 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $183.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $143.25 | 2019-2021 | |
| Astellas Pharma US INC | $141.56 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $136.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $135.14 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.48 | 2019-2021 | |
| Eisai INC. | $91.05 | 2020-2021 | |
| Amarin Pharma, INC. | $90.95 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.78 | 2019-2020 | |
| Esperion Therapeutics, INC. | $55.75 | 2020-2021 | |
| Lilly USA, LLC | $48.12 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $43.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.87 | 2020-2021 | |
| Ethicon US, LLC | $36.57 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $28.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.57 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $20.92 | 2020 | |
| Hikma Pharmaceuticals USA | $20.09 | 2019 | |
| Gilead Sciences, INC. | $17.60 | 2020 | |
| Dexcom, INC. | $16.22 | 2021 | |
| Bardy Diagnostics, INC. | $16.00 | 2020 | |
| Assertio Therapeutics, INC. | $13.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Hodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.